Publications by Oncolines Scientists on ResidenceTimer, QuickScout

  • Kooijman et al. (2022) Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology, 12:953013. https://www.frontiersin.org/articles/10.3389/fonc.2022.953013/full
  • Grobben et al. (2020) Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158. Journal of Structural Biology: X, 4: 100014. https://doi.org/10.1016/j.yjsbx.2019.100014
  • Libouban et al. (2017) Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines, Oncotarget, 8 (24):38309–38325. (collaboration with Netherlands Cancer Institute)
    https://doi.org/10.18632/oncotarget.16213

Publications by Oncolines Scientists on Arginase Gold, NFK Green

References by our Clients to ResidenceTimer™

  • Zalini et al. (2022) BAL0891: a novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division. Poster presentation at AACR Annual Meeting 2022 (Affiliation: Basilea Pharmaceutica International Ltd.)
  • Wentsch et al. (2017) Optimized Target Residence Time: Type 1½Inhibitors for p38a MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine, Angewandte Chemie International Edition, 56 (19):5363-5367. (Affiliations: University of Tübingen, NTRC)
    https://doi.org/10.1002/anie.201701185

References by our Clients to NFK Green™

back to home